Yazarlar : Jegalian AG, Eberle FC, Pack SD, Mirvis M, Raffeld M, Pittaluga S, Jaffe ES.

Yayın : Blood.

Yayın Yılı : 2011

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/21768298

Konu : Radyasyon Onkolojisi

Literatür İçeriği :  

Abstract

Follicular lymphoma in situ (FLIS) was first described nearly a decade ago, but its clinical significance remains uncertain. We reevaluated our original series and more recently diagnosed cases to develop criteria for the distinction of FLIS from partial involvement by follicular lymphoma (PFL). 34 cases of FLIS were identified, most often as an incidental finding in a reactive lymph node. 6/34 patients had prior or concurrent FL, and 5/34 had FLIS composite with another lymphoma. Of patients with negative staging at diagnosis and available follow-up (21 patients), only one (5%) developed FL (follow-up: median 41 mos.; range 10-118 mos.). Follow-up was not available in 2 cases. Fluorescence in situ hybridization for BCL2 gene rearrangement was positive in all 17 cases tested. PFL patients were more likely to develop FL, diagnosed in 9/17(53%) who were untreated. Six patients with PFL were treated with localradiation therapy (4) or rituximab (2) and remained NED. FLIS can be reliably distinguished from PFL, and has a very low rate of progression to clinically significant FL. FLIS may represent the tissue counterpart of circulating t(14;18)-positive B-cells.

Literatür Arşivi